Forget Aurora Cannabis: Here Are 2 Pot Stocks You Can Buy Instead!

Aurora Cannabis is a loss-making company and has burnt massive wealth for investors in the last two years. You can take a look at two profitable growth stocks instead.

| More on:
Cannabis stocks have fallen.

Stocks in the cannabis sector continue to attract investors given the recent wave of legalization south of the border. While Canadian pot stocks have grossly underperformed the broader markets in the last two-and-a-half years, marijuana producers in the U.S. are well poised to deliver outsized gains to long-term investors.

For example, Aurora Cannabis (TSX:ACB)(NYSE:ACB) stock has slumped over 90% from record highs, as it continues to grapple with negative profit margins and falling market share. Due to its massive cash burn and negative EBITDA, Aurora Cannabis has raised equity capital several times over the last few years and has diluted shareholder wealth significantly in the process.

In order to improve the bottom line, Aurora Cannabis is now looking to shift its product mix to focus on high-margin medical marijuana products. However, according to Bay Street estimates, the company is forecast to post a loss per share of $0.76 in fiscal 2022. Given its outstanding shares are close to 198 million, annual losses are forecast at $150 million.

However, there are several profitable pot stocks in the U.S. that are trading on the CSE. Here, we look at two such companies that are better than Aurora Cannabis.

Trulieve Cannabis

One of the most popular growth stocks in this space, Trulieve Cannabis (CNSX:TRUL) is a Florida-based medical marijuana company. It enjoys a market share of 48% in Florida, allowing Trulieve to more than double its sales in the first quarter of 2021.

This pot heavyweight has increased its sales from US$102.8 million in 2018 to US$521.53 million in 2020. Its operating income has also grown from US$75.2 million to US$218.36 million in the process. Analysts expect its sales to rise by 68% year over year to US$877.36 million in 2021 and by 44% to US$1.26 billion in 2022. Its earnings per share are also expected to improve from US$0.53 in 2020 to US$1.62 in 2022.

So, Trulieve Cannabis stock is trading at a forward price-to-2022-sales multiple of 4.8 and a price-to-earnings ratio of 21, which are very reasonable given its spectacular growth forecasts. Trulieve Cannabis stock has an upside potential of over 100% according to consensus price target estimates.

Green Thumb Industries

A multi-state operator in the U.S., Green Thumb Industries (CNSX:GTII) is valued at a market cap of US$6.55 billion. Green Thumb stock is up close to 400% in the last three years and is just getting started.

The cannabis company has 56 dispensaries across 13 states in the United States. It has gained a foothold in Virginia following the acquisition of Dharma Pharmaceuticals.

In the first quarter of 2021, Green Thumb’s revenue surged 89.5% year over year to US$194.4 million, driven by strong demand in states such as Pennsylvania and Illinois as well as the opening of new stores.

Recreational cannabis was legalized in Illinois at the start of 2020, and the state has already generated over $500 million in sales in the first five months of 2021 and remains on track to surpass US$1 billion in annual sales.

Green Thumb has a strong presence in its home state of Illinois. Its adjusted EBITDA grew to US$71 million in Q1, up from US$25.5 million in the year-ago period. Net profit also improved to US$10 million compared to a loss of US$4.2 million in Q1 of 2020. It was the third consecutive quarter of profitable growth for Green Thumb Industries.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Aditya Raghunath has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Green Thumb Industries and Trulieve Cannabis Corp.

More on Cannabis Stocks

Pot stocks are a riskier investment
Cannabis Stocks

The Single-Best Pot Stock to Buy in November 2022

Profitable pot stocks such as Green Thumb are well positioned to deliver market-beating gains to long-term investors in 2022 and…

Read more »

Cannabis smoke
Cannabis Stocks

These 3 Meme Stocks Could Have Legitimate Long-Term Upside

These meme stocks were once a volatile mess of share prices, but now are looking far more valuable these days.

Read more »

A cannabis plant grows.
Cannabis Stocks

5 Things to Know About Cannabis Stocks in November 2022

Cannabis stocks are on the move once more, with U.S. decriminalization and legalization potentially happening across the country.

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

WEED Stock Skyrocketed 62% in 1 Week: Should You Invest?

WEED (TSX:WEED) stock surged 62% in the last week of October, so what's going on with this top pot stock?

Read more »

A cannabis plant grows.
Cannabis Stocks

2 Top Cannabis Stocks to Buy for the Long Haul

U.S.-based cannabis stocks such as Green Thumb and Cresco Labs are top bets for long-term investors with a high-risk appetite.

Read more »

Cannabis smoke
Cannabis Stocks

If I’d Invested $100 in WEED Stock at the Start of 2022, Here’s What I’d Have Now

Shares of Canopy Growth (TSX:WEED) stock are down 70% in 2022. Despite the pullback, it remains a high-risk investment.

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Biden’s Pot Pardon: Where Will Canopy Growth Be in 5 Years?

Joe Biden’s big pro-cannabis push bodes well for Canopy Growth (TSX:WEED) and others this decade.

Read more »

A cannabis plant grows.
Cannabis Stocks

The Single Best Pot Stock to Buy in October

If you can take the wait, this pot stock could be well worth it in the next decade or more,…

Read more »